Philips is a global healthcare company focused on enhancing health and well-being through innovative technologies. Their offerings include advanced imaging systems, ultrasound equipment, and connected care solutions that support patient diagnosis and treatment.
Over the past decade we have transformed into a focused leader in health technology.
At Philips, our purpose is to improve people’s health and well-being through meaningful innovation. We aim to improve 2.5 billion lives per year by 2030, including 400 million in underserved communities.
We see healthcare as a connected whole. Helping people to live healthily and prevent disease. Giving clinicians the tools they need to make a precision diagnosis and deliver personalized treatment. Aiding the patient's recovery at home in the community. All supported by a seamless flow of data.
As a technology company, we – and our brand licensees – innovate for people with one consistent belief: there’s always a way to make life better.
Visit our website: http://www.philips.com/
Follow our social media house rules https://www.philips.com/a-w/about-philips/social-media.html
Amsterdam (Netherlands) 1891 +10000 $4.23B IPO, January 13, 1978 1 year ago
Roche is a leading biopharmaceutical and diagnostic company that develops innovative drugs and diagnostic solutions, particularly in oncology and personalized healthcare. They are also committed to addressing healthcare inequities and improving access to medical innovations for women.
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems.
Burgdorf (Switzerland) 1896 5001 - 10000 NA 1 year ago
GE Healthcare is a prominent medical technology firm specializing in imaging and ultrasound equipment, as well as data analytics and digital solutions. Their offerings include advanced devices and applications aimed at enhancing healthcare outcomes and operational efficiency.
GE Healthcare is a healthcare company with intelligent devices, data analytics, applications, and services-supported intelligence platforms. Their company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity, and improve outcomes for patients, providers, health systems, and researchers around the world.
Helsinki (Finland) 1892 +10000 NA 1 year ago
Johnson & Johnson is a leading healthcare company that develops and sells a wide range of medical devices and pharmaceuticals. Their focus includes innovative solutions aimed at addressing various health challenges across multiple therapeutic areas.
At Johnson & Johnson, we believe health is everything. As a focused healthcare company, with expertise in Innovative Medicine and MedTech, we’re empowered to tackle the world’s toughest health challenges, innovate through science and technology, and transform patient care.
All of this is possible because of our people. We’re passionate innovators who put people first, and through our purpose-driven culture and talented workforce, we are stronger than ever.
Learn more at https://www.jnj.com. Community Guidelines: http://www.jnj.com/social-media-community-guidelines
New Brunswick (United States) 1886 +10000 IPO, September 24, 1944 1 year ago
Ovia Health provides a digital platform with mobile applications focused on fertility, pregnancy, and parenting, supporting women and families throughout their journey. The company aims to enhance health outcomes and empower users to make informed decisions regarding their reproductive health.
Ovia Health by Labcorp offers a leading digital platform dedicated to supporting the full spectrum of women’s health, from preconception through menopause. Our clinical programs provide women with personalized guidance, data-driven insights, and access to over 50 clinical programs and personalized health pathways designed to help improve health outcomes, reduce unnecessary healthcare costs, and support retention and return to work.
Since 2012, we’ve supported millions of women and families on their health and parenthood journeys, offering the only women’s and family health solution proven to effectively identify and intervene with high-risk conditions. Our mission is simple: to help women feel informed, connected, and cared for at every age and stage of life.
Boston (United States) 2011 51 - 200 $23.30M Acquired, August 2021 1 year ago
Kahla develops a comprehensive mobile health application that enhances research, diagnosis, treatment, and care for women's health.
The AI-powered hormone health app for women.
Now available for iOS: http://apple.co/45WoArI
New York (United States) 2021 1 - 10 NA 1 year ago
Safrn Health empowers physicians to improve care for women through its AI-driven platform, enhancing the effectiveness of healthcare delivery.
Developer of an AI-based healthcare platform designed to tackle the costly, chronic condition burden faced by women starting with endocrine disorders. The company's platform reduces the risk of chronic conditions in women, and more, thereby empowering physicians to deliver tailored, and effective care.
Boston (United States) 2022 NA 1 year ago
Grace Health is a digital platform focused on women's health in emerging markets, providing services like cycle tracking, fertility predictions, and access to affordable healthcare. The app aims to empower women with low health literacy by offering personalized health information and support.
Grace Health, owned by Penda Health, is pioneering the health sector with the first-ever digital women’s health clinic designed for the next billion women online. By leveraging high tech mobile technology in a light weight way, we deliver instant access to women’s health services and information at scale. Grace is solving the current problem of accessibility and discretion by delivering a scalable platform to the 1.9 billion women in emerging markets who own their own phone but lack access to women’s health services and information.
Our automated health assistant, Grace, lets women track and understand their reproductive health, get notifications and reminders ahead of time and dive into our extensive educational content. Grace Health also lets women book discounted appointments with an extensive network of local health facilities.
Stockholm (Sweden) 2018 11 - 50 $5.10M Acquired, November 2023 1 year ago
Illumigyn develops a compact imaging device that enhances cervical examinations by providing high-resolution images and multispectral illumination. Their technology aims to improve diagnostic accuracy and reduce misdiagnoses in gynecological care.
illumigyn is a global revolution in women's healthcare - My body, my scan.
illumigyn makes the visit to a gynecologist more effective, pleasant and safe. We bring 21st-Century technology to the world of gynecology.
Neve Ilan (Israel) 2012 11 - 50 $33.00M Venture - Series Unknown, $33.00M, November 3, 2021 1 year ago
Maven Clinic is a digital healthcare platform that provides on-demand support for families during conception, pregnancy, and postpartum. It offers a network of health practitioners and services for various family health needs, including fertility and reproductive care.
Maven is the world's largest virtual clinic for women and families on a mission to make healthcare work for all of us. Maven's award-winning digital programs provide clinical, emotional, and financial support all in one platform, spanning fertility & family building, maternity & newborn care, parenting & pediatrics, and menopause & midlife. More than 2,000 employers and health plans trust Maven's end-to-end platform to improve clinical outcomes, reduce healthcare costs, and provide equity in benefits programs. Recognized for innovation and industry leadership, Maven has been named to the Time 100 Most Influential Companies, CNBC Disruptor 50, Fast Company Most Innovative Companies, and FORTUNE Best Places to Work. Founded in 2014 by CEO Kate Ryder, Maven has raised more than $425 million in funding from top healthcare and technology investors including General Catalyst, Sequoia, Dragoneer Investment Group, Oak HC/FT, StepStone Group, Icon Ventures, and Lux Capital. To learn more about Maven, visit us at mavenclinic.com.
New York (United States) 2014 1001 - 5000 $417.10M Series F+, $125.00M, October 8, 2024 1 year ago
Elektra Health is a digital platform focused on providing evidence-based support and education for women experiencing menopause. It offers telemedicine care, personalized wellness plans, and a community for women navigating this life stage.
Elektra Health is reimagining women's health -- in perimenopause and beyond -- with a virtual care model for women navigating the midlife decades.
Our approach combines evidence-based clinical care, coaching support, and peer community to deliver whole-person, patient-centered care. We build trust and engagement through every step of this often-overlooked life stage.
Elektra partners with over 25 health plans and health systems—including Medicaid, Medicare, and commercial payers—to expand access, close care gaps, and improve outcomes.
Led by seasoned healthcare operators and championed by renowned physicians, Elektra has been featured in The New York Times, Fast Company, Forbes, Vogue, TechCrunch, WSJ, and Fortune, and honored by Maria Shriver, Katie Couric, and Dr. Jill Biden at the White House.
New York (United States) 2019 11 - 50 $12.20M Venture - Series Unknown, $4.65M, February 7, 2025 1 year ago
Vira Health is a digital health company dedicated to enhancing women's long-term health by addressing female-specific conditions. Their primary product, Stella, is an app that provides personalized treatment plans for managing menopause symptoms through evidence-based interventions.
There are 3.8 billion women in the world and they are living longer than ever. We have the opportunity to help more people live happier, healthier, and more productive lives.
At Vira Health, we combine data, clinical best practice, and behavior change to solve the health and quality of life problems that affect billions worldwide.
We believe every woman deserves access to inclusive, comprehensive health support. Our platform brings together the best technology, self-directed care, and clinical intervention across women's health.
Our first product is Stella, an online menopause clinic that supports people through menopause with clinical and behavioral care designed for their specific symptomatic needs.
Menopause costs US women $1.8 billion per year. Despite being one of the fastest growing segments of the workforce, very few are getting the support they need. High-quality menopause care is a crucial component of attracting and retaining senior female talent. In addition to delivering on DE&I goals, it also decreases overall medical expenditure.
Built on proprietary technology, Stella delivers great outcomes with an excellent patient experience while achieving significant ROI.
London (United Kingdom) 2019 11 - 50 $14.06M Series A, $11.97M, March 14, 2022 1 year ago
Flo is a leading application for women's health, providing tools for tracking menstrual cycles, ovulation, and personalized health insights. It also fosters a supportive community for women to share their experiences and concerns.
At Flo, our purpose is to build a better future for female health. We are the world’s leading period and ovulation tracker, empowering over 400 million women globally to take control of their health. With 77 million monthly active users, including 25% of US women, Flo has become a trusted partner in women's health. As the first European femtech unicorn, following a $230M Series C in July 2024, we're proud to lead the way in innovation and investment in women's health.
With over 100+ medical experts, Flo is committed to supporting women at every stage of their health journey, from menstruation to conception, pregnancy, and menopause. We provide curated cycle and ovulation tracking, tailored health insights, daily bite-sized visual content, and a private community for users to share their questions and concerns.
Flo addresses critical challenges in women’s health by:
*Expanding access: Through partnerships like UNFPA, Flo provides free Premium access to up to 1 billion women in 66 countries, with 17 million subscriptions donated, helping bridge healthcare disparities.
*Improving health literacy: By delivering accurate, accessible information and daily insights, Flo empowers millions to better understand their health and make informed decisions.
*Advancing women's health research: Collaborating with leading institutions, Flo contributes to evidence-based women’s health research.
In a world where women's health data is increasingly vulnerable, Flo is dedicated to providing a safe and secure platform. Recognized for its commitment to privacy, Flo's Anonymous Mode feature was named one of TIME's Best Inventions of 2023 and a finalist for Fast Company's 2023 World Changing Ideas Awards. Anonymous Mode allows users to access Flo's health features without associating personal information with their health data, setting a new industry standard for reproductive health data privacy.
London (United Kingdom) 2015 201 - 500 $275.50M Series C, $200.00M, July 30, 2024 1 year ago
Allara provides a virtual care platform focused on holistic management for women with polycystic ovary syndrome, offering services like diagnostic testing, personalized treatment plans, and nutrition counseling. Their team includes board-certified physicians and registered dietitians specializing in women's health.
Allara is the first collaborative care platform for women with chronic health conditions creating a new way for women to get the care they need.
Get started today www.allarahealth.com
Manhattan (United States) 2020 11 - 50 $38.50M Series B, $26.00M, January 24, 2025 1 year ago
Hertility is a women's health company focused on reproductive healthcare, offering unique diagnostic testing and expert advice to enhance understanding of reproductive health and fertility. They provide at-home testing and tailored care pathways to address various reproductive health issues.
Hertility is a women’s health company built by women, for women. We’re shaping the future of reproductive healthcare by pioneering unique diagnostic testing that provides data-driven and advanced insights into reproductive health, fertility decline and the onset of menopause. We provide expert advice, education and access to care - all from the comfort of your home.
Our research trials are a step towards fixing the currently flawed system. 31% of women will suffer from a reproductive health issue at some point and through our research, we aim to reduce the time to diagnosis through advanced at-home testing and specialist gynaecological care. We tailor pathways to the individual's reproductive goals, whether it be to explore their ovarian health and fertility options or overall hormonal health, such as confirming a PCOS diagnosis. Currently, we can diagnose 9 of the most common gynae pathologies which may lead to reduced fertility and signpost gynae cancers.
Ultimately, our aim is to change attitudes around reproductive health, both for individuals and in the workplace, and to encourage women to be proactive by tracking their reproductive health. We’re calling this the Reproductive Revolution!
London (United Kingdom) 2019 11 - 50 $11.26M Non-Equity Assistance, June 6, 2023 1 year ago
The company is dedicated to advancing women's health through non-invasive testing and genetic solutions.
The EMMA Consortium, comprised of Nura Health, Lasa Health, and Dama Health, was created to accelerate innovation in endometriosis care. Our vision is to revolutionize early, non-invasive diagnosis of endometriosis paired with effective personalized treatment, in order to help solve a debilitating chronic condition impacting more than 1 in 10 women worldwide.
The EMMA Consortium, supported by funding from the Advanced Research Projects Agency for Health (ARPA-H), are pioneering a novel solution for endometriosis, combining genetic, clinical, and biomarker data to eliminate delayed diagnosis and ineffective treatments. Our comprehensive precision medicine platform, the Endometriosis Multimodal Management Application (EMMA), accelerates the early diagnosis and personalized treatment of endometriosis by:
* Developing a non-invasive diagnostic test for endometriosis
* Identifying phenotype-driven genetic & biological markers that influence treatment response
* Improve treatment matching for existing and new therapies
We have launched an IRB-approved clinical study, the EMMA study, for women aged 18-50 years old with or without a clinical diagnosis of endometriosis. To learn more and check your eligibility, please visit https://www.lasahealth.com/emma
The EMMA Consortium
----------------------
Nura Health
www.getnura.com
----------------------
Lasa Health
www.lasahealth.com
----------------------
Dama Health
www.damahealth.com
----------------------
Irvine (United States) 2024 1 - 10 $3.00M Grant, $3.00M, October 23, 2024 1 year ago
NxGen MDx enhances women's health through advanced genetic screening and counseling, improving research, diagnosis, and care.
NxGen MDx LLC is a leading women’s health company delivering precise genetic screening through best-in-class science, unrivaled accuracy, and personal genetic counseling.
Unlike other laboratories, NxGen’s technology examines the entire gene rather than parts of the gene, giving families a comprehensive assessment of their true risk. With over 99% accuracy, doctors rely on our best-in-class genetic screens as trusted tools for early family planning.
For more information, visit www.nxgenmdx.com.
Grand Rapids (United States) 2012 51 - 200 NA 1 year ago
The company provides technology-based health solutions and data-driven diagnostics, enhancing women's health care and supporting mobile health applications.
Germany 1 - 10 NA 1 year ago
The company provides AI-driven tools that improve care for women's health, utilizing advanced technology for health management.
Developer of a menopause monitoring application designed to improve women's health. The company's application utilizes artificial intelligence technology and medical science to offer various features, including symptom tracking, hormone balance insights, expert articles and community forums, enabling women to monitor their health throughout their menopause journey and maintain their well-being.
Tokyo (Japan) 2023 1 - 10 NA 1 year ago
Caria enhances care for women during menopause through a supportive platform and utilizes AI technology to improve health management.
Chorus Health is a human-centered healthcare technology company that provides a digital health platform for perimenopausal women and beyond. The company was founded in 2019 and is based in San Francisco, California.
San Francisco (United States) 2019 1 - 10 $120.00K Pre-Seed, $120.00K, September 16, 2019 1 year ago
CGM Genesis excels in improving diagnosis through genetic testing and counseling, while also providing genomic testing services that support personalized healthcare strategies for women.
Spółka Centra Genetyki Medycznej GENESIS to jedna z wiodących firm genetycznych, specjalizująca się w poradnictwie i badaniach genetycznych. Funkcjonuje na rynku usług medycznych nieprzerwanie od ponad 20 lat.
Centra Genetyki Medycznej GENESIS zatrudnia wykwalifikowany zespół lekarzy specjalistów i diagnostów laboratoryjnych, którzy każdego dnia udzielają Pacjentom kompleksowo świadczeń w zakresie poradnictwa i badań genetycznych.
Zespół CGM GENESIS specjalizuje się m.in. w:
• Diagnostyce rzadkich chorób genetycznych
• Diagnostyce poronień, wad wrodzonych, zaburzeń wzrastania, opóźnień rozwoju, niepełnosprawności intelektualnej oraz autyzmu
• Diagnostyce par z niepowodzeniami rozrodu
• Diagnostyce nowotworowej
Lekarze Specjaliści udzielają pacjentom kompleksowej pomocy w obszarze diagnostyki genetycznej. Wizyta w poradni to przede wszystkim fachowa konsultacja lekarska, wsparcie merytoryczne po otrzymaniu wyniku oraz zalecenia profilaktyczne.
Zespół lekarzy i diagnostów zdobywał i nadal poszerza swoje doświadczenie zawodowe w znanych ośrodkach akademickich i instytutach naukowych w kraju oraz w znakomitych ośrodkach badawczych i klinicznych za granicą.
Podmiot leczniczy współpracuje z licznymi ośrodkami naukowymi krajowymi i zagranicznymi oraz stowarzyszeniami pacjentów i ich rodzin.
Jako wiodąca firma genetyczna, pomogła już tysiącom pacjentów z Polski i zagranicy. Udało się to, dzięki posiadaniu zespołu wykwalifikowanych lekarzy specjalistów genetyki klinicznej i diagnostów laboratoryjnych ze specjalizacją z laboratoryjnej genetyki medycznej.
Chcąc dotrzeć do jak najszerszej grupy pacjentów Spółka nieustannie poszerza swoją ofertę badań.
Wykorzystując zaawansowane technologie i najnowsze odkrycia medycyny, każdego dnia dąży do rozwoju stawiając sobie jako wartość nadrzędną ochronę zdrowia i życia naszych pacjentów.
Poznan (Poland) 1997 51 - 200 NA 1 year ago
The company provides digital interventions and applications that improve care and support women's health management.
Digital Care for Women over 40. Coming Soon.
Dover (United States) 2018 1 - 10 NA 1 year ago
Presagen leverages AI to enhance research, diagnosis, treatment, and care in women's health, significantly improving outcomes for patients.
Qubigen’s core business is to use Federated AI to accelerate hit-to-lead and candidate optimization through secure, privacy-preserving analysis of molecular data, advanced virtual screening, and GPU-parallelized quantum chemistry in an end-to-end, real-time application-specific workflow, leading to actionable compounds for tough diseases.
Qubigen's Federated AI accelerates drug design with secure, real-time analysis of molecular data, virtual screening, and GPU-powered quantum chemistry, providing an end-to-end, application-specific platform that delivers actionable compounds for challenging diseases.
Federated AI Engines for drug design enable secure collaboration, transcending institutional data firewalls. Qubigen's FedAIDD can leverage global data without actually moving or seeing it, to build the most intelligent, secure, disease-agnostic AI engines in drug design.
Qubigen’s edge lies in its end-to-end, application-specific workflow and enabling infrastructure. Qubigen transforms that access into actionable, optimized drug candidates, offering a “moat” through patents and domain expertise.
San Francisco (United States) 2016 11 - 50 $6.48M Seed, $2.24M, August 1, 2021 1 year ago
FemiSpace is dedicated to improving women's health through research, personalized treatment programs, and AI-driven solutions.
FemiSpace is the only digital platform that integrates research and personalized AI-based services for women’s general and reproductive health.
Wilmington (United States) 2020 11 - 50 NA 1 year ago
Plackal develops a mobile health application that enhances care for women's health and provides tracking for menstrual cycles.
Plackal develops S/W for mobile devices. Our expertise covers all major platforms - Android, iOS, Windows & Web Apps
Bangalore (India) 2012 11 - 50 NA 1 year ago
